Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.
The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...
Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...
Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...
Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...
Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...
Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...
Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...
Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...